Palvella Therapeutics PVLA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's accrued expenses and other liabilities?
- Palvella Therapeutics (PVLA) reported accrued expenses and other liabilities of -$900K in Q1 2026.
- How has Palvella Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Palvella Therapeutics's accrued expenses and other liabilities increased by 69.1% year-over-year, from -$2.91M to -$900K.
- What is the long-term trend for Palvella Therapeutics's accrued expenses and other liabilities?
- Over 2 years (2021 to 2023), Palvella Therapeutics's accrued expenses and other liabilities has grown at a -65.5% compound annual growth rate (CAGR), from $9.88M to -$1.18M.